FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3115413738> ?p ?o ?g. }

• W3115413738 abstract "Although discontinuation is common in clinical trials, no study has been conducted to analyse the current situation and reasons for the suspension or discontinuation of drug clinical trials in China. This study aims to analyse the general characteristics and reasons for the discontinuation of registered clinical trials in mainland China and to identify the associated factors.We conducted a cross-sectional observational study of discontinued trials registered in the Drug Trial Registration and Information Publication Platform before March 31, 2020. All trials with a status of terminated or stopped recorded in the platform were classified as discontinued trials and included in the analysis. The basic characteristics of the discontinued trials were recorded, reasons for trial discontinuation were recorded and divided into 4 categories as drug development strategy, trial planning, trial conduct and studied drug. Pearson's chi-square test and fisher's exact test were used to compare the differences in reasons for discontinuation between neoplasm trials and non-neoplasm trials, and to examine the associations of trial characteristics with different reasons related to trials discontinuation.Three hundred twelve discontinued trials were included in this study. The studied drugs were mainly chemical drugs [229 (73.4%)], and indications of the studied drugs were mainly neoplasms [77 (24.7%)]. Geographical location of the discontinued trials were mostly in northern [114 (36.5%)] and eastern [96 (30.8%)] China. Study type of the included trials was mainly bioequivalence studies [97 (31.1%)]. The most common reason for trial discontinuation was commercial or strategic decision [84 (26.9%)], followed by futility/lack of efficacy [70 (22.4%)]. The number of trial centers, sample size and whether participants had been enrolled were significantly associated with trial discontinuation (P < 0.05). Multiple center trials showed a higher rate of trial discontinuation due to trial conduct related reasons than single center trials (P < 0.05), trials with sample size > 500 showed a higher rate of trial discontinuation due to studied drug related reasons (P < 0.05), and trials enrolled participants showed a lower rate of trial discontinuation due to commercial or strategic decision and a higher rate of trial discontinuation due to studied drug related reasons than trials without enrolled participants (P < 0.05). Besides, neoplasm trials showed a higher rate of trial discontinuation due to poor recruitment and safety comparing with non-neoplasm trials (P < 0.05).Trial discontinuation in China mainly occurred because of commercial or strategic decision and futility/lack of efficacy of the studied drug. Clinical trials with multiple centers and a large sample size may more likely be discontinued due to trial conduct related reasons such as good clinical practice. Discontinuation due to drug safety and lack of efficacy in multiple center trials with a large sample size deserves more attention to avoid resources wastes. Full communication with regulatory authorities such as Center for Drug Evaluation and research institutes to develop a feasible protocol is important for sponsors to avoid trial discontinuation due to protocol issues." @default.
• W3115413738 created "2021-01-05" @default.
• W3115413738 creator A5010432249 @default.
• W3115413738 creator A5023531721 @default.
• W3115413738 creator A5041047931 @default.
• W3115413738 creator A5055093239 @default.
• W3115413738 creator A5083727099 @default.
• W3115413738 creator A5087099379 @default.
• W3115413738 creator A5091908162 @default.
• W3115413738 date "2021-11-13" @default.
• W3115413738 modified "2023-10-06" @default.
• W3115413738 title "General characteristics and reasons for the discontinuation of drug clinical trials in mainland China" @default.
• W3115413738 cites W1414339606 @default.
• W3115413738 cites W1970223153 @default.
• W3115413738 cites W1975971094 @default.
• W3115413738 cites W2055882248 @default.
• W3115413738 cites W2116823988 @default.
• W3115413738 cites W2122908200 @default.
• W3115413738 cites W2127707591 @default.
• W3115413738 cites W2128251606 @default.
• W3115413738 cites W2490038287 @default.
• W3115413738 cites W2588557959 @default.
• W3115413738 cites W2594789732 @default.
• W3115413738 cites W2607476082 @default.
• W3115413738 cites W2617276441 @default.
• W3115413738 cites W2624735020 @default.
• W3115413738 cites W2741193029 @default.
• W3115413738 cites W2762366935 @default.
• W3115413738 cites W2911484476 @default.
• W3115413738 cites W2982337854 @default.
• W3115413738 cites W2990259541 @default.
• W3115413738 cites W2993885906 @default.
• W3115413738 cites W2997382346 @default.
• W3115413738 doi "https://doi.org/10.1186/s12874-021-01443-2" @default.
• W3115413738 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8590359" @default.
• W3115413738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34773983" @default.
• W3115413738 hasPublicationYear "2021" @default.
• W3115413738 type Work @default.
• W3115413738 sameAs 3115413738 @default.
• W3115413738 citedByCount "0" @default.
• W3115413738 crossrefType "journal-article" @default.
• W3115413738 hasAuthorship W3115413738A5010432249 @default.
• W3115413738 hasAuthorship W3115413738A5023531721 @default.
• W3115413738 hasAuthorship W3115413738A5041047931 @default.
• W3115413738 hasAuthorship W3115413738A5055093239 @default.
• W3115413738 hasAuthorship W3115413738A5083727099 @default.
• W3115413738 hasAuthorship W3115413738A5087099379 @default.
• W3115413738 hasAuthorship W3115413738A5091908162 @default.
• W3115413738 hasBestOaLocation W31154137381 @default.
• W3115413738 hasConcept C126322002 @default.
• W3115413738 hasConcept C187212893 @default.
• W3115413738 hasConcept C23131810 @default.
• W3115413738 hasConcept C2778715236 @default.
• W3115413738 hasConcept C535046627 @default.
• W3115413738 hasConcept C71924100 @default.
• W3115413738 hasConceptScore W3115413738C126322002 @default.
• W3115413738 hasConceptScore W3115413738C187212893 @default.
• W3115413738 hasConceptScore W3115413738C23131810 @default.
• W3115413738 hasConceptScore W3115413738C2778715236 @default.
• W3115413738 hasConceptScore W3115413738C535046627 @default.
• W3115413738 hasConceptScore W3115413738C71924100 @default.
• W3115413738 hasIssue "1" @default.
• W3115413738 hasLocation W31154137381 @default.
• W3115413738 hasLocation W31154137382 @default.
• W3115413738 hasLocation W31154137383 @default.
• W3115413738 hasLocation W31154137384 @default.
• W3115413738 hasLocation W31154137385 @default.
• W3115413738 hasOpenAccess W3115413738 @default.
• W3115413738 hasPrimaryLocation W31154137381 @default.
• W3115413738 hasRelatedWork W1965393569 @default.
• W3115413738 hasRelatedWork W2313076522 @default.
• W3115413738 hasRelatedWork W2330456179 @default.
• W3115413738 hasRelatedWork W2466043692 @default.
• W3115413738 hasRelatedWork W2595635579 @default.
• W3115413738 hasRelatedWork W2765980456 @default.
• W3115413738 hasRelatedWork W2766844642 @default.
• W3115413738 hasRelatedWork W2976382042 @default.
• W3115413738 hasRelatedWork W3206056578 @default.
• W3115413738 hasRelatedWork W2464797648 @default.
• W3115413738 hasVolume "21" @default.
• W3115413738 isParatext "false" @default.
• W3115413738 isRetracted "false" @default.
• W3115413738 magId "3115413738" @default.
• W3115413738 workType "article" @default.